Today: 7 February 2026
Subscribe
Browse Category

Pharma Industry News 23 November 2025 - 3 December 2025

Sun Pharma Advanced Research (SPARC) Stock Soars After US Court Ruling on Sezaby PRV – What the 30% Two‑Day Rally on 3 December 2025 Really Means

Sun Pharma Advanced Research (SPARC) Stock Soars After US Court Ruling on Sezaby PRV – What the 30% Two‑Day Rally on 3 December 2025 Really Means

SPARC stock on 3 December 2025: Still volatile after a 2‑day surge Sun Pharma Advanced Research Company Ltd (SPARC) has exploded back onto traders’ screens this week. On 2 December 2025, the stock hit the 20% upper circuit at around ₹161.10, after a US court delivered a favourable ruling in a long‑running dispute over a Priority Review Voucher (PRV) linked to its neonatal seizure drug, Sezaby. Intra‑day data show around 27.7 million shares changing hands on the BSE, representing roughly 8.5% of the company’s equity, far above normal volumes. Business Standard+1 On 3 December 2025 (mid‑session), the rally extended: Despite
3 December 2025
····
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 as one of the most closely watched large‑cap healthcare stocks, with fresh dividend news, new oncology and migraine data, and an upbeat earnings outlook all hitting the tape just as investors look toward 2026. As of December 2, 2025, AbbVie shares trade around $224–$225 per share, giving the company a market capitalization in the high‑$300 to roughly $400 billion range.TS2 Tech The stock is up roughly 20–30% in 2025, depending on the exact start date used, handily outpacing much of the broader healthcare sector.Barchart.com+2Benzinga+2 Below is a deep dive
2 December 2025
·····
Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

As of late trading on Tuesday, December 2, 2025, Pfizer (NYSE: PFE) shares change hands around $25.10, down roughly 0.7% on the day and sitting in the middle of their 52‑week range of $20.92–$27.69.Yahoo Finance+1 The stock carries a dividend yield close to 7%, reflecting a generous payout but also lingering skepticism about the pharma giant’s growth post‑COVID.Pfizer+1 Today’s price is being shaped by a dense mix of headlines: a fresh FDA push to tighten vaccine oversight, a legal setback for Pfizer’s Seagen unit, the completion of a $10 billion obesity-drug acquisition, and earlier this quarter, upgraded 2025 profit guidance and new oncology approvals.Pfizer+4Investopedia+4Reuters+4 Below is
2 December 2025
·····
Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

As of December 1, 2025. This article is for information only and is not investment advice. JNJ stock today: riding near record highs after a huge 2025 rally Johnson & Johnson (NYSE: JNJ) stock is trading close to its 52‑week high around the low‑$200s per share, giving the healthcare giant a market capitalization of roughly $500–505 billion.PortfoliosLab+1 Over the past 12 months, JNJ has delivered an exceptional total return of about 37–38%, and an eye‑catching ~47% year‑to‑date gain in 2025, dramatically outpacing the S&P 500’s low‑teens 1‑year return.PortfoliosLab+1 Key snapshot as of December 1, 2025:PortfoliosLab+2WallStreetZen+2 In other words, Johnson &
1 December 2025
····
Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Updated November 30, 2025 Pfizer stock is in the middle of a big reset. The COVID windfall is fading, but a massive obesity-drug acquisition, a landmark bladder‑cancer approval and a high dividend yield are reshaping the story investors see in PFE. Pfizer stock price today: valuation snapshot As of the last trading session on Friday, November 28, Pfizer Inc. (NYSE: PFE) closed at $25.74 per share. That gives the company a market capitalization of roughly $146 billion. Investing.com Key current metrics: Pfizer’s share price is still down sharply from its 2021–2022 COVID peak above $50, so even after a modest 2025 rebound, the stock
30 November 2025
····
Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck & Co., Inc. (NYSE: MRK) heads into the Monday, December 1, 2025 market open riding one of the strongest monthly rallies in the S&P 500, powered by upbeat earnings, dividend growth and a string of bullish analyst calls focused on its post‑Keytruda pipeline.Barron’s+1 Below is a detailed look at how MRK is positioned before the bell, based on news, forecasts and analysis published between November 28–30, 2025. Note: This article is for informational and educational purposes only and is not investment advice. 1. Where Merck Stock Stands After November’s Surge Price and recent performance One of November’s standout winners
30 November 2025
····
AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Inc. (NYSE: ABBV) ended Friday’s session almost unchanged, closing around $227.70 per share, up a negligible 0.02%, after earlier trading slightly in the red.StockAnalysis+2StockAnalysis+2 Even with today’s flat finish, the pharma giant remains one of 2025’s standout healthcare names, with year‑to‑date gains of roughly 30–33%, easily beating the S&P 500.Investing.com+1 The calm price action masks a busy news day for AbbVie: Below is a detailed look at what today’s news means for AbbVie stock investors. AbbVie Stock Price and Valuation Snapshot (November 28, 2025) In short, AbbVie trades like a high‑quality, income‑oriented growth stock: pricey on trailing earnings, reasonable
28 November 2025
····
Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk (NYSE: NVO) shares are trying to stabilise after a bruising November as fresh obesity‑drug data, a higher‑dose Wegovy filing and new analyst calls collide with lingering worries about growth and competition. 1. How Novo Nordisk stock is trading today Novo Nordisk’s U.S.-listed ADRs are changing hands around $49.25, up roughly 1% on the day, after trading between $48.35 and $49.75 in Friday’s session. Intraday volume is a little over 6.7 million shares, in line with recent elevated activity. On its home market in Copenhagen, Novo’s B‑shares closed near 317 DKK, up about 2% on the day but still down roughly 49% year to date, according to MarketScreener data. MarketScreener Even after today’s
28 November 2025
···
Eli Lilly (LLY) Stock Outlook Before Market Open on November 28, 2025: Trillion‑Dollar Pharma in Focus

Eli Lilly (LLY) Stock Outlook Before Market Open on November 28, 2025: Trillion‑Dollar Pharma in Focus

As U.S. markets prepare for a shortened Black Friday session on Friday, November 28, 2025, Eli Lilly and Company (NYSE: LLY) will open trading as one of the most closely watched stocks on Wall Street. The drugmaker has just joined the exclusive $1 trillion market‑cap club thanks to explosive demand for its GLP‑1 weight‑loss and diabetes drugs, alongside new momentum in Alzheimer’s disease and oncology. At last trade, Lilly shares were around $1,104 with a market capitalization near $990 billion, giving the company a trailing P/E ratio of roughly 54x earnings and a forward P/E in the mid‑30s—valuations that remain
27 November 2025
···
Eli Lilly (LLY) Stock on November 26, 2025: Trillion‑Dollar Milestone, Pricing Shake‑Up and Stock‑Split Buzz

Eli Lilly (LLY) Stock on November 26, 2025: Trillion‑Dollar Milestone, Pricing Shake‑Up and Stock‑Split Buzz

Eli Lilly and Company (NYSE: LLY) is having another headline‑heavy session on Wednesday, November 26, 2025, as investors digest its new status as the first trillion‑dollar healthcare company, fresh moves on obesity‑drug pricing, and growing chatter about a potential stock split. Reuters+1 As of mid‑afternoon trading, Eli Lilly stock is changing hands around $1,105 per share, down roughly 0.4% on the day, after touching an intraday high above $1,117. That still leaves its market value just over $1 trillion, following a more than 35% rally year to date driven by explosive demand for its GLP‑1 weight‑loss and diabetes drugs Zepbound
26 November 2025
····
Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

As investors head into the Tuesday, November 25 session, Pfizer Inc. (NYSE: PFE) remains one of Wall Street’s most closely watched healthcare names. After a brutal comedown from its pandemic-era highs, the drugmaker is trying to convince the market that a new growth story is taking shape around obesity drugs, oncology and a large – and growing – dividend. As of late Monday trading, Pfizer shares were changing hands around $25 per share, giving the company a market value of roughly $143 billion and placing the stock in the middle of its 52‑week range between $20.92 and $27.69.StockAnalysis+1 At that
25 November 2025
····
Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. (NASDAQ: MRNA) enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out a new three‑year strategy, taking on $1.5 billion in debt, cutting pipeline projects and doubling down on its mRNA platform in respiratory disease and cancer. Reuters+3Financial Times+3Barron’s+3 Here’s a detailed look at Moderna stock today, what changed this week, and how the latest headlines might shape the risk–reward for investors. Moderna stock price snapshot for November 23, 2025 U.S. markets
23 November 2025
·····
1 … 4 5 6 7 8 9

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop